Daiichi Sankyo and AstraZeneca Report the P-III (DESTINY-Breast06) Study Data of Enhertu to Treat Breast Cancer
Shots:
- The P-III (DESTINY-Breast06) study investigates the safety & efficacy of Enhertu (5.4mg/kg) vs CT (capecitabine, paclitaxel or nab-paclitaxel) for the treatment of HR+, HER2 low or ultralow advanced or metastatic breast cancer
- The study demonstrated improved PFS among HER2 low & ultralow metastatic breast cancer patients. Subgroup analysis confirmed consistent improvement in PFS across both HER2 expression groups
- The OS data was immature during the analysis but an early trend in its improvement was established among HER2 low metastatic breast cancer patients & overall population. Further OS & 2EPs evaluation will continue as planned with the results anticipated at future conferences. Plans for regulatory submissions worldwide are underway
Ref: Daiichi Sankyo | Image: Daiichi Sankyo
Related News:- AstraZeneca and Daiichi Sankyo’s Enhertu Receives the US FDA’s Accelerated Approval to Treat Metastatic HER2-Positive Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
